Azitra advances ATR-04 Phase 1/2 trial to Cohort 2 after safety review clearance
AZTR•Azitra cleared Cohort 1 of its Phase 1/2 trial of topical ATR04-484 for EGFR inhibitor-associated skin rash after a safety review, enabling Cohort 2 enrollment and dosing. Cohort 2 targets about 24 patients receiving once-daily dosing for 28 days.
1. Cohort 2 begins
Safety data from Cohort 1 were reviewed, supporting continued development without raising new safety concerns in early dosing. Cohort 2 targets about 24 patients on once-daily dosing for 28 days, with early signs of activity to be assessed later.
